Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial

NCT04394377 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

615

Enrollment

OTHER

Sponsor class

Conditions

Coronavirus Infection

Interventions

DRUG: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed
DRUG: Group 2: control group with enoxaparin 40mg/d

Sponsor

Brazilian Clinical Research Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]